Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $71,939.68 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 1,726 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $41.68, for a total transaction of $71,939.68. Following the transaction, the chief executive officer now directly owns 660,966 shares of the company’s stock, valued at $27,549,062.88. The trade was a 0.26 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Twist Bioscience Stock Down 1.5 %

TWST stock opened at $44.25 on Wednesday. The business’s 50-day moving average price is $45.45 and its 200-day moving average price is $45.36. The stock has a market cap of $2.64 billion, a P/E ratio of -13.09 and a beta of 2.15. Twist Bioscience Co. has a twelve month low of $27.41 and a twelve month high of $60.90. The company has a quick ratio of 4.62, a current ratio of 4.96 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The business had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company’s revenue for the quarter was up 24.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.75) earnings per share. On average, equities research analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Institutional Investors Weigh In On Twist Bioscience

Institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its stake in shares of Twist Bioscience by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock worth $269,860,000 after acquiring an additional 189,791 shares during the period. ARK Investment Management LLC grew its holdings in Twist Bioscience by 4.4% during the 4th quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares in the last quarter. State Street Corp grew its holdings in Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock valued at $143,101,000 after buying an additional 526,028 shares in the last quarter. Thrivent Financial for Lutherans raised its position in shares of Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock valued at $69,972,000 after buying an additional 532,040 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Twist Bioscience by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock worth $63,895,000 after buying an additional 6,908 shares in the last quarter.

Analysts Set New Price Targets

TWST has been the subject of a number of research analyst reports. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. TD Cowen reaffirmed a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Barclays set a $58.00 target price on Twist Bioscience and gave the company an “overweight” rating in a report on Monday, February 3rd. JPMorgan Chase & Co. boosted their price target on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday, February 4th. Finally, Wolfe Research started coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $54.40.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.